Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Here's another interesting Paulsnowman post...
"...there are several outcomes near to hand that should catapult the SP upwards.

1.SP102 full readout (so far we’ve only had topline)

2.Socazolimab China NMPA Approval (expected this month)

3. Abivertinib (NSCLC) China NMPA Approval (application was over a year ago)

4. MSC Brazil EUA (US is likely, but FDA may want to stretch trials to P3 outcome before EUA)

The first 4 outcomes are highly likely, and within Jan / Feb timeframe. While a Abivertinib partnership is highly likely, and SRNE PR over 7 months ago that it’s looking for a global partnership there is no clear timeframe or which BP they maybe in discussions with.

5. Any sale / partnership Abivertinib / mAB / Sofusa / Biobetters / STIX with a BP

6. Actual STIX numbers / cost / revenue / etc… but we’ll most likely have to wait until Annual 10k to get an idea or even 1st quarter earnings. Without actual numbers the naysayers (shorts) will keep on with the manipulation.

7. The actual approval / listing of SPAC will definitely move the SP (likely Feb / March - the biggest headache with SPACS is getting enough shareholders to ok the deal)

Note that SRNE can sell Celularity shares June / July."